

## PHARMACY POLICY STATEMENT

### Marketplace

<b>DRUG NAME</b>	<b>Doptelet (avatrombopag)</b>
BENEFIT TYPE	Pharmacy
STATUS	Prior Authorization Required

Doptelet, approved by the FDA in 2018, is a small molecule thrombopoietin (TPO) receptor agonist indicated for the treatment of thrombocytopenia in adults with chronic liver disease (CLD) who are scheduled to undergo a procedure, and for adults with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. TPO is important for regulating thrombopoiesis. The agonistic effect of Doptelet upregulates the production of platelets. TPO receptor agonists (TPO-RA) have been associated with thrombotic and thromboembolic complications. Doptelet should not be administered in an attempt to normalize platelet counts. Doptelet was the first TPO receptor agonist approved for the indicated CLD population.

Thrombocytopenmen2(e)-14(n)7(m)47(e)-1F2 11.2 Tf 1 0 0 1 108.15 484.5 Tm 0 G [( ) TJ ET Q EMC /P <<



CLD: Added hepatology and GI as accepted specialists. Specified platelet lab must be